Historic Cannabis Banking Hearing Benefits These Companies

Stephen L Kanaval  |

Photo credit:iStockphoto.com/user:FatCamera

Banking is one of the most formidable challenges of the cannabis industry. As many know, since the plant is illegal on the federal level, financial institutions won’t work with business owners even if their business resides in a legal state. This has turned legal business owners into pseudo-gangsters who are responsible to transport millions of dollars in cash to vaults or state facilities.

Cannabis business owners might want to buy a few more armored trucks as Nielsen just wrote a report estimating U.S. cannabis sales to reach $41 billion by 2025 due to the popularity of CBD products nationwide.

With all this cash going toward cannabis products, a Senate Committee on Banking, Housing and Urban Affairs held a hearing on July 23rd about passing the Secure And Fair Enforcement (SAFE) Banking Act.

Historic hearing probably for naught

The legislation, sponsored by Democratic Senator, Jeff Merkley, from Oregon, would safeguard against cannabis businesses from being charged with money laundering and other financial crimes.

Many voices were heard including Matt Hawkins, from Cresco Capital Partners, who gave an investment perspective on passing the SAFE Banking Act.

"We could potentially see a heavy influx of cannabis-related IPO registrations to the New York Stock Exchange and NASDAQ," he said. "This bill would also open the floodgates for the billions of dollars in revenue generated from the industry to be integrated into the federal banking system. Taxation and money transfers will become smoother and quicker, and this will ultimately allow for loans to be issued to business owners, as well as workers in the industry who would then be able to more easily acquire loans for education, housing and more.”

However, even with all the witnesses - many attesting to the issues of crime and ramifications of locking legitimate business owners out of the financial system - and strong support for a companion bill in the House, the Senate is unlikely to pass.

“I remain pessimistic unless and until somebody signals to me that either Sen. (Mitch) McConnell, as the leader of the Senate, or his caucus is strongly supportive (of reform),” said Douglas Berman, director of Ohio State University’s Drug Enforcement and Policy Center.

Who benefits?

So, with a banking industry that will probably remain on the sidelines, cannabis companies with the most cash in-hand should see the most growth, whereas many mid-level operators will have to sell stock to keep up.

The industry’s own factors are partly to blame. Cannabis is reaching a point of oversupply quicker than anticipated. Export volumes are not there yet and in some states like Oregon legal producers are using only 50% of their running supply. As a whole, Oregon has 1.3 million pounds of cannabis it can’t move due to Federal laws barring its transfer across state lines. Current estimates are that Oregon will be in a state of oversupply until 2025.

With this stagnant banking situation and investor interest waning, cannabis operators with the most liquidity will be able to strategically adjust and capitalize on opportunities ahead. One of the largest opportunities approaching has to do with edibles and infusions becoming legal in Canada in October. And, of course, those with the most cash are some familiar names:

  1. Canopy Growth (CGC) - $3.6 billion
  2. Cronos Group (CRON) – $1.82 billion
  3. GW Pharmaceuticals (GWPH) - $592 million
  4. Tilray (TLRY) - $518 million
  5. Aurora Cannabis (ACB) - $379 million

It is worth noting that there is quite a big difference between Canopy and Aurora, which has made it commonplace to dilute shareholders to close a deal, but we could be looking at an upcoming cannabis market where the rich only get richer.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

I, or a firm that employs me, am a holder of the following securities securities mentioned in this article : none

Companies

Symbol Name Price Change % Volume
CGC Canopy Growth Corporation 24.89 -0.24 -0.96 7,223,351 Trade
GWPH GW Pharmaceuticals Plc 145.46 -1.89 -1.28 296,375 Trade
CRON Cronos Group Inc. 11.40 -0.18 -1.55 3,487,020 Trade
TLRY Tilray Inc. 28.29 -0.72 -2.48 2,399,714 Trade
ACB Aurora Cannabis Inc. 5.64 -0.15 -2.59 9,228,744 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.